Nuchev Pty Ltd · ASX:NUC
Nuchev Pty — H1 FY21 Earnings Presentation
13 slides from Nuchev Pty's earnings presentation, Feb 22, 2021
Slide 1: Nuchev Limited HY21 Half Year Results
Nuchev Limited HY21 Half Year Results February 2021 1
Slide 2: Food for a better life
Food for a better life 2 2
Slide 3: Today's presenters and agenda
Today’s presenters Agenda Business strengths 4 Financial and business highlights 5 Financial Performance 6 Ben Dingle CEO, Executive Director and Founder Outlook 8 Appendix 10 Chantelle Pritchard CFO and Company Secretary 3
Slide 4: Business strengths remain in place
Business strengths remain in place Significant global market opportunity Premium, differentiated product, Oli6® is a premium, trusted, supported by science Australian made and owned brand ▪ Goat milk based infant formula (GIF) is a rapidly growing segment of the infant formula (IF) market ▪ GIF offe
Slide 5: H1 FY21 Financial & Business Performance
H1 FY21 Financial & Business Performance Volumes (Metric Tonnes) Encouraging signs of recovery from challenging market conditions caused by 265.7 COVID-19 ▪ Revenue declined 33% on prior corresponding period due to impacts of ongoing COVID-19 171.0 restrictions and broader economic uncertainty ▪ How
Slide 6: Key financial and operational metrics
Key financial and operational metrics 1H21 1H20 % Change Commentary ▪ Strong revenue growth in CBEC channel following successful transition to new strategic Volume (MT)1 171 266 (33%) distribution partner Blue Ocean International. Revenue ($ million)1 5.4 8.1 (33%) ▪ Orders through the Export channe
Slide 7: Outlook
Outlook 7
Slide 8: Outlook for H2 FY2021
Outlook for H2 FY2021 Executive Leadership Team changes enable stronger focus on domestic and international growth ▪ Given Nuchev’s growth aspirations in both the domestic and international markets, the company has confirmed a number of changes to its’ Executive Leadership Team to ensure it has the
Slide 9: Slide 9
Slide 10: Appendix
Appendix 10
Slide 11: Statutory profit and loss (HY21 and HY20)
Statutory profit and loss (HY21 and HY20) Statutory Results for the 6 months ending: Commentary ▪ H1 Distribution related expenses 7% of Revenue up on FY20 $ millions Notes H1 FY21 % of H1 FY20 % of mainly due to the reduction in sales base and therefore Revenue Revenue lower economies of scale, how
Slide 12: Consolidated statement of financial position as at 31/12/20 and 31/12/19
Consolidated statement of financial position as at 31/12/20 and 31/12/19) Consolidated statement of financial position as at: Commentary $ millions 31 Dec 2020 31 Dec 2019 ▪ Nuchev has $17.6 million cash as at 31 December 2020 Cash and short term deposits 17.6 15.2 with successful capital raise in A
Slide 13: Disclaimer
Disclaimer This presentation is provided by Nuchev Limited (ACN 163 225 090) (Nuchev) to provide summary information about Nuchev and its respective subsidiaries (together, the Group). Statements in this presentation are made as at the date of the presentation and the information in this presentatio